FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model
Sarah R. Mudd(AbbVie (United States)), Mark L. Day(Royal Society for the Protection of Birds), Daniel H. Albert(AbbVie (United States)), Paul Tapang(AbbVie (United States)), Marion Refici-Buhr(Abbott (United Kingdom)), Gerard B. Fox(Purdue University West Lafayette), Yanping Luo(Abbott Fund), Martin J. Voorbach(AbbVie (United States)), Jonathan A. Hickson(AbbVie (United States)), David R. Reuter(AbbVie (United States))
Cited by 5
Related Papers
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541
Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor
|Journal of Medicinal Chemistry|2008|140
A quantitation method for mass spectrometry imaging
|Rapid Communications in Mass Spectrometry|2011|92